Anti-platelet aggregation pharmaceutical composition

An anti-platelet aggregation and composition technology, which is applied in drug combinations, active ingredients of heterocyclic compounds, blood diseases, etc., can solve the problems of coumarin-drug interactions without research reports

Active Publication Date: 2014-12-03
INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, there have been no research reports on the interaction between coumarin drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-platelet aggregation pharmaceutical composition
  • Anti-platelet aggregation pharmaceutical composition
  • Anti-platelet aggregation pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1, the preparation of the pharmaceutical composition of anti-platelet aggregation

[0022] According to the molar concentration ratio of each component shown in Table 1, cinnamic acid, p-coumaric acid and coumarin were weighed and mixed to obtain a pharmaceutical composition.

[0023] Table 1 Molar concentration ratio of each component

[0024]

Embodiment 2

[0025] Embodiment 2, the experiment of the inhibitory effect of pharmaceutical composition on ADP-induced platelet aggregation

[0026] 1. Preparation of anticoagulation buffer Buffer A

[0027] Sodium chloride 130mmol / L, sodium citrate 10mmol / L, sodium bicarbonate 9mmol / L, glucose 6mmol / L, magnesium chloride 0.9mmol / L, potassium dihydrogen phosphate 0.81mmol / L, trishydroxymethylaminomethane 10mmol / L L mixed to prepare anticoagulation buffer solution Buffer A.

[0028] 2. Preparation of the pharmaceutical composition solution

[0029] a. Add Buffer A to the pharmaceutical composition of test number 1 to form a pharmaceutical composition solution 1 with a coumarin molar concentration of 720 μM;

[0030] b. Add Buffer A to the pharmaceutical composition of test number 2 to form a pharmaceutical composition solution 2 with a coumarin molar concentration of 640 μM;

[0031] c. Add Buffer A to the pharmaceutical composition of test number 3 to form a pharmaceutical composition s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
control rateaaaaaaaaaa
Login to view more

Abstract

The invention provides an anti-platelet aggregation pharmaceutical composition comprising cinnamic acid, p-coumaric acid and coumarin, wherein the molar concentration ratio of the cinnamic acid to the p-coumaric acid to the coumarin is (1-9):(1-9):(4-36). The experiment result shows that the inhibiting effect on ADP-induced platelet aggregation caused by combined utilization of the cinnamic acid, the p-coumaric acid and the coumarin is obviously higher than that caused by independent use of the coumarin.

Description

technical field [0001] The invention belongs to the field of medicines, in particular to a pharmaceutical composition for anti-platelet aggregation. Background technique [0002] Under physiological conditions, platelets in the undamaged vascular system do not undergo activation and aggregation, and have the function of protecting endothelial cells and preventing the formation of cardiovascular diseases such as atherosclerosis. Platelet aggregation plays a key role in the normal coagulation mechanism, but when it deforms abnormally, adheres, and aggregates, it can form a thrombus. For example, when platelets are stimulated by agonists such as thrombin (THR), they are activated, aggregate, form thrombus, and lead to cardiovascular events. During cerebral ischemia-reperfusion, oxygen free radicals and other signaling molecules can activate inflammatory cytokines, cause the release of chemokines, and upregulate adhesion molecules, which in turn lead to enhanced platelet adhesi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P7/02A61K31/192
Inventor 杨洪军郭宇飞
Owner INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap